Keros Therapeutics
Update in progressKROS (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies that modulate TGF-β family signaling to treat disorders from dysfunctional signaling. It is advancing rinvatercept, a ligand trap for myostatin and activin A, in Phase 1 for Duchenne muscular dystrophy and ALS; and elritercept for TGF-β–related hematopoietic diseases in Phase 3 for myelodysplastic syndromes and Phase 2 for myelofibrosis. Collaborations include Hansoh Shanghai Healthtech and Takeda. Founded 2015, based in Lexington, MA.
Company score
- Sentiment
- -0.41
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.38
- Governance
- -0.10
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.13
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.27
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationUnited States
- CEODr. Jasbir S. Seehra Ph.D.
- Founded2015
- Employees92
- Websitewww.kerostx.com
Identifiers
- ISINUS4923271013
- FIGIBBG00H1HP9G9
- CUSIP492327101
- CIK0001664710